Opportunity Information: Apply for PAR 19 360
This NIH grant opportunity, titled "Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)" (Funding Opportunity Number PAR-19-360), supports research that digs into a very practical problem in cancer prevention and immunization: a clinician recommending the HPV vaccine is one of the strongest drivers of adolescent vaccination, but that recommendation does not always happen, and even when it does, it does not always translate into actual vaccine uptake. The focus of the announcement is the healthcare delivery system itself, looking at how the way care is organized, delivered, and experienced can either strengthen or weaken the impact of a provider's recommendation on whether adolescents initiate and complete the HPV vaccine series. The overall goal is to produce evidence that can help close the gap between recommendation and real-world vaccination, ultimately reducing HPV-related cancers.
The FOA emphasizes that HPV vaccine uptake is not determined by a single factor; it is shaped by interacting characteristics across three main domains: the provider, the parent/patient, and the clinical setting. Provider-related influences can include communication style, strength and clarity of the recommendation, comfort addressing vaccine concerns, time pressures, competing priorities during visits, training, implicit bias, and how clinicians interpret guidelines. Parent and patient factors can include beliefs about vaccines, cancer risk perceptions, trust in healthcare, health literacy, prior experiences, cultural norms, concerns about safety or sexual activity misconceptions, and practical barriers such as transportation or scheduling. Clinical setting factors can include clinic workflow, reminder and recall systems, use of standing orders, electronic health record prompts, team-based care models, availability of same-day vaccination, after-hours access, billing and reimbursement processes, and whether preventive care is consistently integrated into adolescent visits. The NIH is looking for research that connects these system and contextual factors directly to whether provider recommendations occur and whether they successfully lead to vaccination.
Because the problem sits at the intersection of behavior, prevention, and healthcare operations, the announcement signals a need for multidisciplinary research teams. It highlights expertise areas such as cancer prevention, adult and child or adolescent behavior, immunization promotion, and healthcare delivery or health services research. In practice, that points to studies that can combine clinical insights with implementation science, behavioral science, communication research, and health systems engineering, and that can evaluate interventions or strategies in real clinical environments. The activity mechanism is the R01 (research project grant), and clinical trials are optional, meaning applicants may propose either observational, mixed-methods, or intervention studies, including trials, as long as the design fits the research questions and the NIH definition of a clinical trial if applicable.
Eligibility is broad across public, private, nonprofit, and for-profit entities in the United States. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education and private institutions of higher education; federally recognized Native American tribal governments; other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses); small businesses; and other eligible entities. The FOA also explicitly calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, Asian American Native American Pacific Islander Serving Institutions, faith-based or community-based organizations, regional organizations, eligible federal agencies, tribal governments other than federally recognized entities, and U.S. territories or possessions. At the same time, it clearly restricts foreign involvement: non-U.S. organizations and non-U.S. institutions are not eligible to apply, non-U.S. components of U.S. organizations are not eligible, and foreign components (as NIH defines them) are not allowed under this announcement.
Administratively, this is a discretionary grant opportunity from the National Institutes of Health. The funding activity category is listed under education and health, and the associated CFDA numbers are 93.393 and 93.395. The FOA record shows a creation date of August 29, 2019, and an original closing date of September 7, 2022, indicating it was part of a defined application window or cycle during that period. While the provided record does not specify an award ceiling or expected number of awards, the intent is clearly to fund rigorous R01-level research that can explain and improve the pathway from clinician recommendation to adolescent HPV vaccination, with attention to real-world healthcare delivery conditions and the multiple human factors that influence vaccination decisions.Apply for PAR 19 360
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.395.
- This funding opportunity was created on 2019-08-29.
- Applicants must submit their applications by 2022-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional) - PAR-19-360
What is the goal of this NIH funding opportunity?
The goal is to support research that explains and improves the real-world pathway from a clinician recommending the HPV vaccine to adolescents actually starting and completing the HPV vaccine series. The overall public health intent is to help close the gap between recommendation and vaccine uptake and ultimately reduce HPV-related cancers.
What is the official title and funding opportunity number?
The opportunity is titled "Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)" and the Funding Opportunity Number is PAR-19-360.
Which agency is offering this grant?
This is a discretionary grant opportunity from the National Institutes of Health (NIH).
What type of grant mechanism is used?
The activity mechanism is an R01 (research project grant).
Are clinical trials required under this FOA?
No. Clinical trials are optional. Applicants may propose observational, mixed-methods, or intervention studies, including trials, as long as the design fits the research questions and aligns with the NIH definition of a clinical trial if applicable.
What problem is this FOA trying to address?
The FOA addresses the practical issue that clinician recommendation is one of the strongest drivers of adolescent HPV vaccination, but recommendations do not always occur and, even when they do, they do not always result in vaccine initiation or completion.
What is the main focus: individuals or the healthcare delivery system?
The main focus is the healthcare delivery system, including how care is organized, delivered, and experienced, and how those conditions strengthen or weaken the impact of a provider recommendation on vaccine uptake.
What domains of factors does the FOA highlight as shaping HPV vaccine uptake?
The FOA highlights interacting factors across three main domains: provider factors, parent/patient factors, and clinical setting factors.
What provider-related factors are specifically mentioned?
Examples include communication style; strength and clarity of the recommendation; comfort addressing vaccine concerns; time pressures; competing priorities during visits; training; implicit bias; and how clinicians interpret guidelines.
What parent and patient factors are specifically mentioned?
Examples include beliefs about vaccines; cancer risk perceptions; trust in healthcare; health literacy; prior experiences; cultural norms; concerns about safety or misconceptions about sexual activity; and practical barriers such as transportation or scheduling.
What clinical setting factors are specifically mentioned?
Examples include clinic workflow; reminder and recall systems; standing orders; electronic health record prompts; team-based care models; availability of same-day vaccination; after-hours access; billing and reimbursement processes; and whether preventive care is consistently integrated into adolescent visits.
What kinds of studies does NIH appear to be seeking under this announcement?
Studies that connect healthcare system and contextual factors directly to whether provider recommendations occur and whether those recommendations successfully lead to HPV vaccination. The FOA points to research conducted in real clinical environments and can include observational, mixed-methods, or intervention approaches.
Why does the FOA emphasize multidisciplinary research teams?
The issue sits at the intersection of behavior, prevention, and healthcare operations. The FOA signals a need for teams that can combine relevant expertise (for example, cancer prevention, behavioral science, immunization promotion, and healthcare delivery/health services research) to study and improve vaccination outcomes in real-world settings.
What expertise areas are specifically highlighted?
The FOA highlights expertise areas such as cancer prevention; adult and child or adolescent behavior; immunization promotion; and healthcare delivery or health services research.
Is eligibility limited to universities?
No. Eligibility is broad and includes many types of U.S.-based public, private, nonprofit, and for-profit entities.
What U.S. government entities are eligible to apply?
Eligible applicants include state, county, city, township, and special district governments, as well as independent school districts.
Are higher education institutions eligible?
Yes. Public and state-controlled institutions of higher education and private institutions of higher education are eligible.
Are tribal entities eligible?
Yes. Federally recognized Native American tribal governments are eligible, and the FOA also calls out tribal governments other than federally recognized entities and other tribal organizations as eligible applicant types.
Are nonprofits eligible, including those without 501(c)(3) status?
Yes. Nonprofits with or without 501(c)(3) status are eligible.
Are for-profit organizations eligible?
Yes. For-profit organizations (other than small businesses) are eligible, and small businesses are also eligible.
Are community-based or faith-based organizations eligible?
Yes. The FOA explicitly includes faith-based or community-based organizations as eligible applicant types.
Are Minority Serving Institutions (MSIs) explicitly included?
Yes. The FOA explicitly calls out Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, and Asian American Native American Pacific Islander Serving Institutions.
Are U.S. territories or possessions eligible?
Yes. The FOA explicitly includes U.S. territories or possessions as eligible applicant types.
Are foreign organizations eligible to apply?
No. Non-U.S. organizations and non-U.S. institutions are not eligible to apply under this announcement.
Can a U.S. organization include a non-U.S. component?
No. Non-U.S. components of U.S. organizations are not eligible under this announcement.
Are foreign components allowed in any form?
No. Foreign components (as NIH defines them) are not allowed under this FOA.
What is the CFDA listing for this opportunity?
The associated CFDA numbers are 93.393 and 93.395.
When was the FOA record created and when did it close?
The FOA record shows a creation date of August 29, 2019, and an original closing date of September 7, 2022, indicating it operated within a defined application window or cycle during that period.
Does the provided record list an award ceiling or the expected number of awards?
No. The provided record does not specify an award ceiling or an expected number of awards.
What funding activity category is associated with the opportunity?
The funding activity category is listed under education and health.
What outcomes is this FOA ultimately trying to influence?
The FOA is ultimately aimed at improving adolescent HPV vaccine initiation and completion by strengthening the effect of provider recommendations within real-world healthcare delivery conditions, contributing to prevention of HPV-related cancers.
Browse more opportunities from the same category: Education, Health
Next opportunity: Science of Learning and Augmented Intelligence (SL)
Previous opportunity: Science of Artificial Intelligence – Basic and Applied Research for the Naval Domain
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 19 360
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 19 360) also looked into and applied for these:
| Funding Opportunity |
|---|
| Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional) Apply for PAR 19 358 Funding Number: PAR 19 358 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional) Apply for PAR 19 352 Funding Number: PAR 19 352 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial Optional) Apply for PAR 19 359 Funding Number: PAR 19 359 Agency: National Institutes of Health Category: Education, Health Funding Amount: $50,000 |
| Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01 Clinical Trial Not Allowed) Apply for PAR 19 361 Funding Number: PAR 19 361 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Apply for PAR 19 363 Funding Number: PAR 19 363 Agency: National Institutes of Health Category: Education, Health Funding Amount: $499,999 |
| Revision Applications for Mechanisms of Drug Resistance (R01 Clinical Trials Not Allowed) Apply for RFA CA 19 049 Funding Number: RFA CA 19 049 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Revision Applications for Mechanisms of Drug Resistance (U01 Clinical Trials Not Allowed) Apply for RFA CA 19 050 Funding Number: RFA CA 19 050 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Revision Applications for Mechanisms of Drug Resistance (U54 Clinical Trials Not Allowed) Apply for RFA CA 19 051 Funding Number: RFA CA 19 051 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Revision Applications for Mechanisms of Drug Resistance (P01 Clinical Trials Not Allowed) Apply for RFA CA 19 052 Funding Number: RFA CA 19 052 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Revision Applications for Mechanisms of Drug Resistance (P50 Clinical Trials Not Allowed) Apply for RFA CA 19 053 Funding Number: RFA CA 19 053 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) Apply for PAR 19 368 Funding Number: PAR 19 368 Agency: National Institutes of Health Category: Education, Health Funding Amount: $499,999 |
| Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38) (Clinical Trial Not Allowed) Apply for RFA HL 20 006 Funding Number: RFA HL 20 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required) Apply for RFA CA 19 056 Funding Number: RFA CA 19 056 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| The Rat Opioid Genome Project: Clinical Trials not Allowed (U01- Clinical Trial Not Allowed) Apply for RFA DA 20 010 Funding Number: RFA DA 20 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Improving the Reach and Quality of Cancer Care in Rural Populations (R01 Clinical Trial Required) Apply for RFA CA 19 064 Funding Number: RFA CA 19 064 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Omics-guided Biobehavioral Interventions for Improved Health Outcomes: A Step Forward in Translation (R01 Clinical Trial Optional) Apply for PAR 19 377 Funding Number: PAR 19 377 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Informatics Technology for Cancer Research Education Center (UE5 Clinical Trials Not Allowed) Apply for RFA CA 19 042 Funding Number: RFA CA 19 042 Agency: National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| Research Networks for the Study of Recovery Support Services for Persons Treated with Medications for Opioid Use Disorder (R24 Clinical Trial Optional) Apply for RFA DA 20 014 Funding Number: RFA DA 20 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) Apply for RFA DA 20 026 Funding Number: RFA DA 20 026 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional) Apply for PAR 19 381 Funding Number: PAR 19 381 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 19 360", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.